Literature DB >> 306410

Role of viral infectivity in the induction of influenza virus-specific cytotoxic T cells.

T J Braciale, K L Yap.   

Abstract

This report examines the requirement for infectious virus in the induction of influenza virus-specific cytotoxic T cells. Infectious influenza virus was found to be highly efficient at generating both primary and secondary cytotoxic T-cell response in vivo. Inactivated influenza virus however, failed to stimulate a detectable cytotoxic T-cell response in vivo even at immunizing doses 10(5)-10(6)-fold higher than the minimum stimulatory dose of infectious virus. Likewise inactivated virus failed to sensitize target cells for T cell-mediated lysis in vitro but could stimulate a specific cytotoxic response from primed cells in vitro. Possible requirements for the induction of virus-specific cytotoxic T-cell responses are discussed in light of these observations and those of other investigators.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 306410      PMCID: PMC2184234          DOI: 10.1084/jem.147.4.1236

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  33 in total

1.  BEHAVIOR OF VIRUS-SPECIFIC ACTIVITIES IN TISSUE CULTURES INFECTED WITH MYXOVIRUSES AFTER CHEMICAL CHANGES OF THE VIRAL RIBONUCLEIC ACID.

Authors:  C SCHOLTISSEK; R ROTT
Journal:  Virology       Date:  1964-02       Impact factor: 3.616

2.  Non-infectious virus induces cytotoxic T lymphocytes and binds to target cells to permit their lysis.

Authors:  J C Palmer; L J Lewandowski; D Waters
Journal:  Nature       Date:  1977-10-13       Impact factor: 49.962

3.  Cytotoxic T cells specific for influenza virus-infected target cells.

Authors:  K L Yap; G L Ada
Journal:  Immunology       Date:  1977-02       Impact factor: 7.397

4.  Cytotoxic T cells to type A influenza virus; viral hemagglutinin induces A-strain specificity while infected cells confer cross-reactive cytotoxicity.

Authors:  H J Zweerink; B A Askonas; D Millican; S A Courtneidge; J J Skehel
Journal:  Eur J Immunol       Date:  1977-09       Impact factor: 5.532

5.  T-cell cytotoxicity in the absence of viral protein synthesis in target cells.

Authors:  U Koszinowski; M J Gething; M Waterfield
Journal:  Nature       Date:  1977-05-12       Impact factor: 49.962

6.  In vitro evidence of cell-mediated immunity after exposure of mice to both live and inactivated rabies virus.

Authors:  T J Wiktor; P C Doherty; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1977-01       Impact factor: 11.205

7.  Immunologic recognition of influenza virus-infected cells. II. Expression of influenza A matrix protein on the infected cell surface and its role in recognition by cross-reactive cytotoxic T cells.

Authors:  T J Braciale
Journal:  J Exp Med       Date:  1977-09-01       Impact factor: 14.307

8.  Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses.

Authors:  R B Effros; P C Doherty; W Gerhard; J Bennink
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

9.  Joint recognition by cytotoxic T cells of inactivated Sendai virus and products of the major histocompatibility complex.

Authors:  J W Schrader; G M Edelman
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

10.  Antibody to influenza virus matrix protein detects a common antigen on the surface of cells infected with type A influenza viruses.

Authors:  W E Biddison; P C Doherty; R G Webster
Journal:  J Exp Med       Date:  1977-09-01       Impact factor: 14.307

View more
  42 in total

Review 1.  Beyond the classical: influenza virus and the elucidation of alternative MHC class II-restricted antigen processing pathways.

Authors:  Laurence C Eisenlohr; Nancy Luckashenak; Sebastien Apcher; Michael A Miller; Gomathinayagam Sinnathamby
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

2.  Do L3T4+ T cells act as effector cells in protection against influenza virus infection.

Authors:  S Lightman; S Cobbold; H Waldmann; B A Askonas
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

3.  Influenza virus-infected epithelial cells present viral antigens to antigen-specific CD8+ cytotoxic T lymphocytes.

Authors:  H H Nguyen; P N Boyaka; Z Moldoveanu; M J Novak; H Kiyono; J R McGhee; J Mestecky
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 4.  Virus entry and antigen biosynthesis in the processing and presentation of class-II MHC-restricted T-cell determinants of influenza virus.

Authors:  C J Hackett; L C Eisenlohr
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

5.  Generation of cytolytic T lymphocytes after reovirus infection: role of S1 gene.

Authors:  R Finberg; H L Weiner; B N Fields; B Benacerraf; S J Burakoff
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

Review 6.  Distinguishable pathways of viral antigen presentation to T lymphocytes.

Authors:  L A Morrison; V L Braciale; T J Braciale
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

7.  Frequency of cytotoxic T lymphocyte precursors to herpes simplex virus type 1 as determined by limiting dilution analysis.

Authors:  B T Rouse; H S Larsen; H Wagner
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

8.  Selective induction of immunological tolerance in antiviral T killer cells of inbred mice after treatment with cyclosporin A.

Authors:  D Armerding
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

9.  The induction of murine cytotoxic T lymphocytes by bluetongue virus.

Authors:  M H Jeggo; R C Wardley
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

10.  Intranasal flu vaccine protective against seasonal and H5N1 avian influenza infections.

Authors:  Mohammed Alsharifi; Yoichi Furuya; Timothy R Bowden; Mario Lobigs; Aulikki Koskinen; Matthias Regner; Lee Trinidad; David B Boyle; Arno Müllbacher
Journal:  PLoS One       Date:  2009-04-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.